Suppr超能文献

致命性新冠肺炎中心脏损伤及心脏微血栓的分子病理生理学:来自临床病理及单核RNA测序分析的见解

Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses.

作者信息

Fukuma Nobuaki, Hulke Michelle L, Brener Michael I, Golob Stephanie, Zilinyi Robert, Zhou Zhipeng, Tzimas Christos, Russo Ilaria, McGroder Claire, Pfeiffer Ryan, Chong Alexander, Zhang Geping, Burkhoff Daniel, Leon Martin B, Maurer Mathew, Moses Jeffrey W, Uhlemann Anne-Catrin, Hibshoosh Hanina, Uriel Nir, Szabolcs Matthias J, Redfors Björn, Marboe Charles C, Baldwin Matthew R, Tucker Nathan R, Tsai Emily J

出版信息

bioRxiv. 2021 Jul 27:2021.07.27.453843. doi: 10.1101/2021.07.27.453843.

Abstract

Cardiac injury is associated with critical COVID-19, yet its etiology remains debated. To elucidate the pathogenic mechanisms of COVID-19-associated cardiac injury, we conducted a single-center prospective cohort study of 69 COVID-19 decedents. Of six cardiac histopathologic features, microthrombi was the most commonly detected (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi. Using single nuclei RNA-sequence analysis, we discovered an enrichment of pro-thrombotic/anti-fibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling amongst cardiac fibroblasts in microthrombi-positive COVID-19 hearts relative to microthrombi-negative COVID-19. Non-COVID-19 non-failing hearts were used as reference controls. Our cumulative findings identify the specific transcriptomic changes in cardiac fibroblasts as salient features of COVID-19-associated cardiac microthrombi.

摘要

心脏损伤与重症新型冠状病毒肺炎(COVID-19)相关,但其病因仍存在争议。为阐明COVID-19相关心脏损伤的发病机制,我们对69例COVID-19死亡患者进行了一项单中心前瞻性队列研究。在六种心脏组织病理学特征中,微血栓是最常检测到的(n = 48,70%)。我们测试了心脏微血栓与炎症、心脏损伤和纤维蛋白溶解生物标志物以及院内抗血小板治疗、治疗性抗凝和皮质类固醇治疗之间的关联,同时对包括COVID-19治疗在内的多种临床因素进行了调整。住院期间较高的血沉方程K值(ESR)峰值和C反应蛋白(CRP)与微血栓形成几率较高独立相关。通过单核RNA序列分析,我们发现与微血栓阴性的COVID-19心脏相比,微血栓阳性的COVID-19心脏中心肌成纤维细胞中促血栓形成/抗纤维蛋白溶解、细胞外基质重塑和免疫增强信号富集。非COVID-19非衰竭心脏用作参考对照。我们的累积研究结果确定了心肌成纤维细胞中的特定转录组变化是COVID-19相关心脏微血栓的显著特征。

相似文献

3
Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study.
Circulation. 2021 Mar 9;143(10):1031-1042. doi: 10.1161/CIRCULATIONAHA.120.051828. Epub 2021 Jan 22.
4
COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart.
Circulation. 2021 Jan 19;143(3):230-243. doi: 10.1161/CIRCULATIONAHA.120.050754. Epub 2020 Nov 16.
6
Cardiac pathology in COVID-19: a single center autopsy experience.
Cardiovasc Pathol. 2021 Sep-Oct;54:107370. doi: 10.1016/j.carpath.2021.107370. Epub 2021 Jul 14.
8
COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies.
Front Cardiovasc Med. 2021 Jan 28;7:626975. doi: 10.3389/fcvm.2020.626975. eCollection 2020.
9
A Unique Case of Acute Coronary Syndrome in a Patient With COVID-19 Infection.
Cureus. 2021 Jun 14;13(6):e15650. doi: 10.7759/cureus.15650. eCollection 2021 Jun.
10
Reperfusion therapy in out-of-hospital cardiac arrest: current insights.
Resuscitation. 2007 May;73(2):189-201. doi: 10.1016/j.resuscitation.2006.08.030. Epub 2007 Jan 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验